Strategic Diversification Redefines Lilly’s Post-GLP-1 Growth Blueprint
Eli Lilly’s agreement to acquire Ventyx Biosciences for $1.2 billion marks a deliberate shift in how the world’s most valuable drugmaker is planning for life beyond its unprecedented obesity and diabetes windfall. After years in which GLP-1 medicines transformed Lilly’s revenue base and investor expectations, the company is signaling that its next phase of growth…









